Posted inDiabetes & Endocrinology news Urology
Metformin Did Not Prevent Metabolic Syndrome During ADT but Improved Weight, Waist and HbA1c: Findings from the PRIME Phase 3 Trial
In the PRIME randomized phase 3 trial, metformin did not significantly reduce metabolic syndrome incidence in men starting androgen deprivation therapy, but produced modest, clinically relevant reductions in body weight, waist circumference, and hemoglobin A1c.













